Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
Pharmacomechanical thrombolysis can be particularly effective in mitigating post-thrombotic syndrome (PTS) in younger patients, as demonstrated by data from the ATTRACT trial.
In the GUIDED study, pharmacogenomic testing significantly improved response and remission rates for difficult-to-treat depression patients over the standard of care.
In this video, recorded at the World Stem Cell Summit 2019, Julie Allickson, PhD, discusses past and current research conducted at the Wake Forest University School of Medicine’s…
New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
The proportion of risk for alcohol use disorder (AUD) that can be attributed to genetic factors is as high as 60%. This data invokes heritability comparisons to both…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
The Centers for Disease Control and Prevention (CDC) has produced a new video for healthcare providers who treat or dispense medications to women of reproductive age. This short…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
